Clinical Trial Update: Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Failed in Previous Therapy [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial is planned to evaluate donafenib in combination with immunotherapy and local therapy for unresectable hepatocellular carcinoma that has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Donafenib (donafenib)

Snippet

Sponsor: Tongji Hospital | Conditions: Unresectable Hepatocellular Carcinoma | Phase 4 | Status: NOT_YET_RECRUITING